Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To assess the association between subretinal hyperreflective material (SHRM), atrophy, and intraretinal fluid (IRF) in pachychoroid neovasculopathy (PNV).
Design: Retrospective observational study.
Subjects: A total of 120 eyes diagnosed with PNV and treated with anti-vascular endothelial growth factor for more than 1 year.
Methods: Central macular thickness (CMT), best-corrected visual acuity (BCVA), and the presence of SHRM, atrophy, fibrosis, subretinal fluid (SRF), and IRF were assessed at baseline, 3 months, and 1 year. SHRM and atrophy areas were also quantitatively measured. Comparisons were made between eyes with SHRM (SHRM [+]) and without SHRM (SHRM [-]) at baseline.
Main Outcome Measures: Incidence and area of SHRM, development of atrophy and fibrosis, presence and resolution of IRF and SRF, changes in CMT and BCVA.
Results: At baseline, 57 eyes (47.5%) exhibited SHRM, which regressed in 85% after 1 year. Atrophy developed in 40% of eyes at 1 year, with 83.3% occurring in SHRM (+) eyes. Fibrosis was observed in 21.7% of eyes, with 92.3% in SHRM (+). IRF was more prevalent in SHRM (+) (all P ≤ 0.010) and showed limited resolution compared with SRF (McNemar P = 0.099 vs. P < 0.001). SHRM (+) eyes had thinner CMT and worse BCVA.
Conclusion: SHRM at baseline was associated with the development of atrophy, fibrosis, and IRF in PNV. Although most SHRM regressed after treatment, it frequently resulted in residual atrophy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajo.2025.08.048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Subretinal Hyperreflective Material, Atrophy, and Intraretinal Fluid in Pachychoroid Neovasculopathy.
Am J Ophthalmol
August 2025
Nune eye center, Seoul, Republic of Korea.
Purpose: To assess the association between subretinal hyperreflective material (SHRM), atrophy, and intraretinal fluid (IRF) in pachychoroid neovasculopathy (PNV).
Design: Retrospective observational study.
Subjects: A total of 120 eyes diagnosed with PNV and treated with anti-vascular endothelial growth factor for more than 1 year.
Quantitative Assessment of En‑face OCT‑Derived Minimum Intensity Fluid Changes Following Ranibizumab Biosimilar Therapy in Macular Neovascularization Secondary to nAMD and PCV.
Clin Ophthalmol
July 2025
Department of Retina Services, Shantilal Shanghvi Eye Institute, Mumbai, India.
Purpose: This retrospective study aimed to evaluate the efficacy of a new regulatory approved ranibizumab biosimilar (RzB), Oceva (Sun Pharmaceutical Industries Limited, Mumbai, India), in treating macular neovascularization secondary to neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), using Minimum-Intensity based changes observed on en-face optical coherence tomography (OCT) (en-face MI OCT).
Patients And Methods: Thirty-six eyes with treatment-naïve MNV underwent three loading doses of RzB. Best-corrected visual acuity (BCVA) and the proportions of eyes with subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hyperreflective material (SHRM) were assessed.
Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy.
Ophthalmol Ther
September 2025
School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Introduction: This study aimed to evaluate the anatomical and functional outcomes of switching to intravitreally administered brolucizumab (Beovu, Novartis) in patients affected by pachychoroid neovasculopathy (PNV) who were considered as non-responders to previous anti-vascular endothelial growth factor (anti-VEGF) therapies, defined as the persistence of intraretinal fluid (IRF), subretinal fluid (SRF), or subretinal hyper-reflective material (SHRM).
Methods: Twenty-three eyes of 21 patients with exudative PNV, who were switched to brolucizumab between April 2021 and December 2023, were retrospectively enrolled. All patients had previously received at least one injection of another anti-VEGF agent.
Quantification of Optical Coherence Tomography Features in >3500 Patients with Inherited Retinal Disease Reveals Novel Genotype-Phenotype Associations.
medRxiv
July 2025
Institute of Ophthalmology, University College London, 11-43 Bath Street, London, UK.
Purpose: To quantify spectral-domain optical coherence tomography (SD-OCT) images cross-sectionally and longitudinally in a large cohort of molecularly characterized patients with inherited retinal disease (IRDs) from the UK.
Design: Retrospective study of imaging data.
Participants: Patients with a clinical and molecularly confirmed diagnosis of IRD who have undergone macular SD-OCT imaging at Moorfields Eye Hospital (MEH) between 2011 and 2019.
Real-world outcomes of a loading phase with intravitreal faricimab in refractory Neovascular Age-Related Macular Degeneration (nAMD) patients.
BMC Ophthalmol
July 2025
Eye Center, The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
Background: Intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents is the standard of care for neovascular age-related macular degeneration (nAMD), but treatment resistance and incomplete fluid resolution remain challenges in refractory cases. This study investigates the real-world outcomes of faricimab in patients with previously treated refractory nAMD.
Methods: A prospective single center study was conducted involving patients with refractory nAMD treated with a loading dose of 3 IVI of faricimab 6 mg/0.